STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the “Company”), ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Life on Earth possesses an exceptional ability to self-reproduce, which, even on a simple cellular level, is driven by ...

Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new ...

Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced exciting preliminary Phase 1 ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

4basebio made notable strides in product supply for clinical trials, providing opDNA™ to HelixNano Technologies Inc. for an mRNA vaccine trial and supplying high-quality and GMP-grade synthetic DNA to ...

The Board of 4basebio plc is pleased to report the results for the financial year ended 31 December 2024. The annual report and accounts together with a notice of the Company’s annual general meeting, ...

Biomedical engineers at Georgia Tech created a treatment that could one day unlock a universal strategy for treating some of ...

Giving scientists direct control over DNA and mRNA synthesis timelines ... of cutting-edge solutions for health and technology. These breakthroughs in synthetic biology could help accelerate ...

Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases with epidemic implications “It is very encouraging to see strong ...

synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment via intratumoral delivery. Strand dosed their first ...